Other Clinical Trial - Prolonged Clinical Follow-up of OPTIMA-5

Status Completed

Clinical Trial Summary

The OPTIMA-5 trial is a prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose recombinant staphylokinase (r-SAK) with normal saline (NS) in patients with ST-segment elevation myocardial infarction (STEMI) presenting ≤12 hours of symptom onset and expected to undergo primary percutaneous coronary intervention (PPCI) within 120 minutes. The results of OPTIMA-5 showed that a single bolus r-SAK prior to PPCI for STEMI improves infarct related artery (IRA) patency and reduces infarct size without increasing major bleeding. On this basis, this study was designed to investigate the effect of the novel reperfusion strategy on 1-year outcomes of patients with STEMI.

Clinical Trial Description

Acute myocardial infarction (AMI) is one of the leading causes of death all over the world, and accounted for more than 100 thousand deaths in the US in 2019. Early PPCI reduces mortality in patients with STEMI. If PPCI cannot be performed within 120 minutes of presentation, guidelines recommend the use of thrombolytic therapy. However, it remains uncertain whether adjunctive thrombolytic therapy administered immediately prior to PPCI improves outcomes in patients undergoing the procedure within 120 minutes. SAK is a fibrin specific fibrinolytic agent produced by Staphylococcus aureus that was first discovered in 1948. A recombinant form of SAK was approved by China Food and Drug Administration (CFDA) for treatment of patients with STEMI. It has been demonstrated that r-SAK is more potent than urokinase and recombinant streptokinase in rabbit models. The OPTIMA-5 trial is an investigator-initiated, prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose r-SAK with NS in patients with STEMI presenting ≤12 hours of symptom onset and expected to undergo PPCI within 120 minutes. Between October 29, 2021 and August 14, 2022, 283 STEMI patients were screened in 8 centers in China and 200 were randomized to r-SAK group or control in a 1:1 ratio using a computer-generated randomization sequence. On this basis, this study was aimed to conduct a 1-year follow-up study to further confirm the efficacy and safety of this novel reperfusion strategy for patients with STEMI. ;

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
ST-segment Elevation Myocardial Infarction (STEMI)

Clinical Trial Details

NCT number	NCT05649696
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact
Status	Completed
Phase	Phase 4
Start date	October 29, 2021
Completion date	October 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04962178` - Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset	N/A
Not yet recruiting	`NCT04549766` - Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
Not yet recruiting	`NCT05511831` - The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI	Phase 4
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT01144819` - Platelet Inhibition in the Acute Phase of STEMI	N/A
Recruiting	`NCT03539133` - Systemic Organ Communication in STEMI
Completed	`NCT01642667` - Pharmacoinvasive Therapy With Prourokinase	Phase 2/Phase 3
Completed	`NCT04131816` - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program	N/A
Recruiting	`NCT03768453` - EARLY-MYO-CMR Registry
Completed	`NCT04942977` - Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy	N/A
Recruiting	`NCT04912518` - Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction	N/A
Completed	`NCT04996901` - The Chinese STEMI PPCI Registry (CSPR)
Recruiting	`NCT05892042` - Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction	N/A
Completed	`NCT02197117` - Effect of Remote Ischemic Conditioning in Heart Attack Patients	N/A
Completed	`NCT02733341` - The Effect of IV Cangrelor and Oral Ticagrelor Study	Phase 4
Not yet recruiting	`NCT04110691` - Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
Recruiting	`NCT05510661` - Use of Export in Primary Percutaneous Coronary Intervention	N/A
Recruiting	`NCT05709626` - PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction	Phase 4
Recruiting	`NCT05046483` - Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Active, not recruiting	`NCT04828681` - Angio-IMR and Cardiac MR-derived MVO in STEMI Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.